Brief: Clene Reports Topline Results Of Phase 2 Covid-19 Study Of CNM-ZnAg

Clene

27/12/2022 21:55

Dec 27 (Reuters) - Clene Inc.  CLNN.O :
    * CLENE NANOMEDICINE REPORTS TOPLINE RESULTS OF PHASE 2
COVID-19
STUDY OF CNM-ZNAG
    * CLENE INC. - PRIMARY ENDPOINT OF TIME TO SUBSTANTIAL
SYMPTOM
RESOLUTION WAS NOT MET IN ACUTELY SYMPTOMATIC, NON-HOSPITALIZED
COVID-19 PATIENTS
    * CLENE INC. - CNM-ZNAG TREATMENT WAS SAFE AND
WELL-TOLERATED
    * CLENE INC. - WILL CEASE FURTHER DEVELOPMENT FOR COVID
    * CLENE INC. - CONTINUE FOCUS ON TREATMENT OF
NEURODEGENERATIVE
DISEASES WITH LEAD ASSET, CNM-AU8

Source text for Eikon:  ID:nGNXc7v7QQ 
Further company coverage:  CLNN.O 
 ((Reuters.Briefs@thomsonreuters.com;))